摘要
目的探讨切除修复交叉互补基因1(ERCC1)、着色性干皮病基因(XPD)多态性与晚期非小细胞肺癌(NSCLC)患者含铂二药方案化疗敏感性的关系。方法采用PCR-RFLP方法检测130例以铂类药物为基础化疗方案的晚期NSCLC患者ERCC1 118C/T、C8092A与XPD Asn312Asp、Lys751Gln基因多态性,分析其与化疗敏感性的关系。结果化疗2个周期后,130例患者的客观缓解率(ORR)为33.8%(44/130),其中部分缓解(PR)44例(33.8%),疾病稳定(SD)54例(41.6%),疾病进展(PD)32例(24.6%)。ERCC1 118C/T+T/T基因型化疗ORR(52.4%)是C/C基因型(41.8%)的3.300倍[95%CI(1.104,9.864),P=0.003]。XPD Asp312Asn、Lys751Gln(或Gln751Gln)基因型化疗ORR(62.5%)是其他基因型的(29.2%)的3.922倍[95%CI(1.320,11.649),P=0.010]。ERCC1 118C/T(或T/T)、XPD Asp312Asn与Lys751Gln(或Gln751Gln)基因型化疗ORR(58.0%)是ERCC1 118C/C、XPD Asp312Asp与Lys751Lys基因型的(31.8%)的3.571倍[95%CI(1.082,11.793),P=0.032]。应用SHEsis分析软件发现以其他单体型组为参照,A-C单体型化疗ORR显著提高(P=0.039)。结论 ERCC1 118C/T和XPD Asp312Asn、Lys751Gln多态性与晚期NSCLC患者铂类药物化疗敏感性密切相关。
Objective To investigate the relationship between genetic polymorphism of excision repair cross - comple- menting （ ERCCI ） and xeroderma pigmentosum group D （XPD） and platinum - based chemotherapy in advanced non - small cell lung cancer （NSCLC） . Methods Genetic polymorphisms of ERCC1 118 C/T, C8092A and XPD Asn312Asp, Lys751Gln were detected by PCR - RFLP method in 130 patients with advanced NSCLC who received platinum - based chemotherapy and the relationship between genetic polymorphisms of ERCC1 and XPD and chemotherapy sensitivity was analyzed. Results After two chemotherapy cycles, the overall response rate is 33. 8% （44/130）, including 44 PR （33.8%）, 54 SD （41.6%） and 32 PD （ 24. 6% ） . The ERCC1 118 C/T ＋ T/T carriers were 3. 300 times as sensitive to the chemotherapy as the C/C genotype [ 95% CI （ 1. 104, 9. 864）, P =0. 003] . The XPD Asp312Asn and Lys751Gln （or Gln751Gln） carriers were 3. 922 times as sensitive to the chemotherapy as the other types [95%CI （1.320, 11.649）, P =0.010] .The ERCC1 118 C/T （or T/T）, XPD Asp312Asn and Lys751 Gin （or Gln751 Gin） polymorphism carriers were 3. 571 times as sensitive to the chemotherapy as the ER- CC1 118 C/C, XPD Asp312Asp and Lys751Lys polymorphism carriers [ 95% CI （1. 082, 11. 793 ）, P = 0. 032 ] . The effec- tive rate of chemotherapy of the patients with A - C haplotype were significantly increased compared with other haplotypes （ P = 0.039） . Conclusion There is close relationship between polymorphism in ERCC1 ll8C/T and polymorphisms in XPD Asp312Asn, Lys751 Gin and response of patients with advanced NSCLC receiving platinum- based chemotherapy.
出处
《中国全科医学》
CAS
CSCD
北大核心
2012年第9期1010-1014,共5页
Chinese General Practice
基金
辽宁省自然科学基金(20082084)
关键词
癌
非小细胞肺
切除修复交叉互补基因1
着色性干皮病基因
多态性
单核苷酸
抗肿瘤联合化疗方案
Carcinoma, non - small cell lung
Excision repair cross - complementing 1
Xeroderma pigmentosumgroup D
Polymorphism, single nucleotide
Antineoplastic combined chemotherapy protocols
作者简介
通讯作者：许崇安，E-mail：cmu4h-xca@126．com
